Full-Time

Staff Systems Engineer

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$195k - $205k/yr

+ Bonus + Stock Options

Pleasanton, CA, USA

In Person

On-site 4–5 days per week required; minimal travel (<10%).

Category
Biology & Biotech (1)
Required Skills
Risk Management
Requirements
  • Bachelor’s degree in Mechanical Engineering, Biomedical Engineering, or related field; Master’s or PhD strongly preferred.
  • 12+ years of experience in medical device development, with significant ownership of system architecture.
  • Demonstrated expertise in fluidics, including irrigation, aspiration, pressure and flow control, and vacuum systems.
  • Strong hands-on experience with both: Single-use disposable systems; Capital equipment incorporating pumps, sensors, and closed-loop control.
  • Deep understanding of positive and negative pumping technologies and their control strategies.
  • Experience architecting systems that integrate hardware, disposables, and software.
  • Proven ownership of system-level requirements and verification.
  • Proficiency with Jama (or equivalent), dFMEAs, fault-tree analysis, and requirements traceability.
  • Strong working knowledge of relevant medical device standards (e.g., ISO 14971, IEC 62304, IEC 60601 family).
  • Track record of writing high-quality, testable requirements that scale across complex systems.
  • Staff-level technical judgment and decision-making capability.
  • Ability to lead through influence and technical authority rather than direct reporting lines.
  • Clear, concise technical communicator across disciplines and experience levels.
  • Comfortable operating in ambiguity, making informed trade-offs, and driving alignment.
  • Location: Pleasanton, CA (on-site presence expected 4–5 days per week)
  • Travel: Minimal (<10%)
Responsibilities
  • Serve as the architect and technical owner of the system with strong focus on the fluidic performance.
  • Define the end-to-end system architecture encompassing capital equipment, endoscopes, disposable tubing sets, sensors, pumps (positive and negative), and control software.
  • Establish and control system interfaces, including fluidic, mechanical, electrical, and software-control boundaries.
  • Drive architectural trade studies using bench testing, prototyping, and simulation to validate design decisions.
  • Ensure architectural robustness across intended use, misuse, fault conditions, and edge cases.
  • Own creation, maintenance, and verification of system-level requirements, with particular emphasis on fluidic performance, safety, and reliability.
  • Decompose user, clinical, and business needs into clear, testable system and subsystem requirements across: Disposable fluid paths; Pumping and flow-control subsystems; Sensors and feedback loops.
  • Ensure complete traceability from user needs through requirements, risks, mitigation, and verification.
  • Write requirements that are technically precise, non-prescriptive, and verification-ready.
  • Lead identification and mitigation of system-level fluidic risks, including pressure excursions, occlusions, leaks, compliance variability, air management, and failure modes across reusable and disposable components.
  • Own or significantly contribute to system-level dFMEAs, ensuring strong linkage between requirements, risk controls, and verification activities.
  • Define and support system-level verification strategies, ensuring requirements are objectively testable and clinically relevant.
  • Actively de-risk novel or critical aspects of the system through early experimentation and focused learning cycles.
  • Serve as the fluidics and systems subject-matter expert across mechanical, electrical, firmware, software, clinical, quality, and product teams.
  • Lead architecture reviews, requirements reviews, and system-level design discussions.
  • Work closely with other technical leads (mechanical, electrical, and SW) to ensure a fully functional system.
  • Provide clear technical direction and interface control to external development partners, ensuring alignment with Calyxo’s system architecture and verification strategy.
  • Mentor engineers on systems thinking, requirement quality, and architectural rigor.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.